Literature DB >> 32738062

Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia.

Miguel Germán Borda1,2,3, Dag Aarsland1,4, Diego Alejandro Tovar-Rios5,6, Lasse M Giil7, Clive Ballard8, Maria Camila Gonzalez1,9, Kolbjørn Brønnick1,3, Guido Alves9,10,11, Ketil Oppedal1,12,13, Hogne Soennesyn1, Audun Osland Vik-Mo1,14.   

Abstract

BACKGROUND/
OBJECTIVES: Functional status is one of the most important markers of well-being in older adults, but the drivers of functional decline in dementia are not well known. The aim of our work was to study the association of neuropsychiatric symptoms (NPSs) with functional decline over 5 years in newly diagnosed people with Alzheimer´s disease (AD) and Lewy body dementia (LBD).
DESIGN: Secondary analysis of the Dementia Study of Western Norway longitudinal cohort study.
SETTING: Multicenter study conducted in memory clinics in western Norway. PARTICIPANTS: We included a total of 196 patients newly diagnosed with AD (n = 111) and LBD (n = 85), followed up annually for 5 years. MAIN OUTCOMES AND MEASURES: The outcome was the rapid disability rating scale (items 1-13). Linear mixed-effects models were used for analysis with the total score of the Norwegian Neuropsychiatric Inventory (NPI) as a predictor measured either at baseline or longitudinally, adjusted for potential confounders, including cognition. Effect modification was checked by introducing interactions with NPI score and stratifying by diagnosis.
RESULTS: The total NPI score longitudinal course was associated with functional decline in both AD and LBD. At baseline, the total NPI score predicted functional decline in AD.
CONCLUSION: NPSs were associated with the rate of functional decline in people with AD and LBD, independent of cognitive impairment. These results highlight the relevance of early detection and intervention of NPSs, which may also reduce functional decline. J Am Geriatr Soc 68:2257-2263, 2020.
© 2020 The American Geriatrics Society.

Entities:  

Keywords:  Alzheimerʼs disease; Lewy body dementia; dementia; functional status; neuropsychiatric symptoms

Year:  2020        PMID: 32738062     DOI: 10.1111/jgs.16709

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  3 in total

1.  The impact of medication reviews by general practitioners on psychotropic drug use and behavioral and psychological symptoms in home-dwelling people with dementia: results from the multicomponent cluster randomized controlled LIVE@Home.Path trial.

Authors:  Marie H Gedde; Bettina S Husebo; Janne Mannseth; Mala Naik; Geir Selbaek; Maarja Vislapuu; Line Iden Berge
Journal:  BMC Med       Date:  2022-05-26       Impact factor: 11.150

2.  Specific agitation behaviours in dementia differentially contribute to aspects of caregiver burden.

Authors:  Karlee S Patrick; John Gunstad; John T Martin; Kimberly R Chapman; Jennifer Drost; Mary Beth Spitznagel
Journal:  Psychogeriatrics       Date:  2022-07-19       Impact factor: 2.295

3.  Assessing Nigrostriatal Dopaminergic Pathways via 123I-FP-CIT SPECT in Dementia With Lewy Bodies in a Psychiatric Patient Cohort.

Authors:  Niels Hansen; Claudia Lange; Charles Timäus; Jens Wiltfang; Caroline Bouter
Journal:  Front Aging Neurosci       Date:  2021-06-21       Impact factor: 5.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.